Cell Therapy News Volume 12.19 | May 16 2011

Study Finds Therapies Using Induced Pluripotent Stem Cells Could Encounter Immune Rejection Problems
Biologists have discovered that induced pluripotent stem cells could face immune rejection problems if they are used in future stem cell therapies. [Press release from the University of California, San Diego discussing online prepublication in Nature]

Human Lung Stem Cell Discovered
Researchers have identified a human lung stem cell that is self-renewing and capable of forming and integrating multiple biological structures of the lung including bronchioles, alveoli and pulmonary vessels. [Press release from Brigham and Women’s Hospital discussing online prepublication in the New England Journal of Medicine]

Reprogrammed Cells Repair Damaged Livers
Cells taken from the tips of mouse tails and genetically reprogrammed to mimic mature liver cells can repair damaged livers. [Press release from NatureNews discussing online prepublication in Nature]

Non-Human Primate Studies Reveal Promising Vaccine Approach for HIV
A research team produced a vaccine candidate that programs the immune system of non-human primates to respond more swiftly to the presence of a primate version of Human Immunodeficiency Virus (HIV) than it normally would. [Press release from Oregon Health & Science University discussing online prepublication in Nature]

“Fasting Pathway” Points the Way to New Class of Diabetes Drugs
A uniquely collaborative study uncovered a novel mechanism that turns up glucose production in the liver when blood sugar levels drop, pointing towards a new class of drugs for the treatment of metabolic disease. [Press release from the Salk Institute for Biological Studies discussing online prepublication in Cell]

From a Single Adult Cell, Flatworm Crafts a New Body
A single adult cell from one of the most impressive masters of regeneration in the animal kingdom – the planarian – is all it takes to build a completely functional new worm, researchers have learned. [Press release from Howard Hughes Medical Institute discussing online prepublication in Science]

Scientists Design New Anti-Flu Virus Proteins Using Computational Methods
A research article demonstrates the use of computational methods to design new antiviral proteins not found in nature, but capable of targeting specific surfaces of flu virus molecules. [Press release from the University of Washington discussing online prepublication in Science]

New Combination Therapy Eradicates Prostate Cancer In Vivo
Cancer researchers are a step closer to finding a cure for advanced prostate cancer after effectively combining an anti-cancer drug with a viral gene therapy in vivo using novel ultrasound-targeted microbubble-destruction technology. [Press release from Virginia Commonwealth University Massey Cancer Center discussing online prepublication in the Proceedings of the National Academy of Sciences USA]

New Marker Offers Hope for More Reliable Detection of Prostate Cancer
A new, promising marker for diagnosing prostate cancer has been discovered by researchers with the aid of a unique method. [Press release from Uppsala Universitet discussing online prepublication in the Proceedings of the National Academy of Sciences USA]

Winding Back the Clock with Kidney Stem Cells
For the first time, scientists have shown that they can make human stem cells from healthy adult kidneys without working on human embryos, circumventing ethical concerns around this research. [Press release from Monash University discussing online prepublication in the Journal of the American Society of Nephrology]

Scientists Discover New Method for Engineering Human Tissue Regeneration
Scientists provide evidence to support a major paradigm shift in this specialty area from the idea that cells added to a graft before implantation are the building blocks of tissue, to a new belief that engineered tissue constructs can actually induce or augment the body’s own reparative mechanisms, including complex tissue regeneration. [Press release from EurekAlert! discussing online prepublication in The FASEB Journal]

New Antibody for Cell Labeling: Stem Cells Can Be Distinguished on the Basis of Sugar Residues
Researchers have produced an antibody that allows them to distinguish the numerous types of stem cells in the nervous system better than before. [Press release from ScienceDaily discussing online prepublication in The Journal of Biological Chemistry]

Scientists Use Genetically Altered Virus to Get Tumors to Tattle on Themselves
Scientists have used a genetically re-engineered herpes virus that selectively hunts down and infects cancerous tumors and then delivers genetic material that prompts cancers to secrete a biomarker and reveal their presence. [Press release from the Cincinnati Children’s Hospital Medical Center discussing online prepublication in PLoS One]

Scientists for the First Time Regenerate Sections of Retinas and Increase Visual Function with Stem Cells Derived from Skin
Scientists are the first to regenerate large areas of damaged retinas and improve visual function using induced pluripotent stem cells derived from skin. [Press release from Schepens Eye Research Institute discussing online prepublication in PLoS One]

Adult Stem Cells Take Root in Livers and Repair Damage
Researchers have demonstrated that human liver cells derived from adult cells coaxed into an embryonic state can engraft and begin regenerating liver tissue in mice with chronic liver damage. [Press release from Johns Hopkins Medicine discussing online prepublication in Science Translational Medicine]

Stem Cells from Bone Marrow Save the Day
New research investigates the therapeutic use of human stem cells from bone marrow against acute lung injury and identifies TNF-α-induced protein 6 as a major molecular component of stem cell action. [Press release from EurekAlert! discussing online prepublication in Stem Cell Research & Therapy]

Stem Cell Technology Used in Unique Surgery
For the first time ever in the world, researchers have produced a blood vessel from stem cells and then
used it in an operation on a 10-year-old girl. [University of Gothenburg Press Release]

Engineer Builds Tissue Models to Study Diseases
Shelly Peyton, a chemical engineer, is building working models of human bone, breast, liver and artery tissues to see how cells behave when they are affected by a disease such as cancer. The ultimate goal of the research is to develop new drug therapies to fight diseases with a streamlined testing regimen that may not require animal testing, she says. [University of Massachusetts Amherst Press Release]

Evidence for Human Lung Stem Cells
Surgical lung-tissue specimens were studied in situ to identify and characterize human lung stem cells. Scientists defined their phenotype and functional properties in vitro and in vivo. [N Engl J Med]

Induction of Functional Hepatocyte-Like Cells from Mouse Fibroblasts by Defined Factors
Researchers demonstrate the direct induction of functional hepatocyte-like cells from mouse tail-tip fibroblasts by transduction of Gata4, Hnf1α and Foxa3, and inactivation of p19^Arf. [Nature]

Immunogenicity of Induced Pluripotent Stem Cells
Scientists show that, whereas embryonic stem cells (ESCs) derived from inbred C57BL/6 (B6) mice can efficiently form teratomas in B6 mice without any evident immune rejection, the allogeneic ESCs from 129/SvJ mice fail to form teratomas in B6 mice due to rapid rejection by recipients. [Nature]

Profound Early Control of Highly Pathogenic SIV by an Effector Memory T-Cell Vaccine
Scientists report that simian immunodeficiency virus (SIV) vaccines that include rhesus cytomegalovirus vectors establish indefinitely persistent, high-frequency, SIV-specific effector memory T-cell responses at potential sites of SIV replication in rhesus macaques and stringently control highly pathogenic SIVMAC239 infection early after mucosal challenge. [Nature]

Class IIa Histone Deacetylases Are Hormone-Activated Regulators of FOXO and Mammalian Glucose Homeostasis
Researchers show that in liver, class IIa histone deacetylases (HDACs) (HDAC4, 5, and 7) are phosphorylated and excluded from the nucleus by AMPK family kinases. [Cell]

Clonogenic Neoblasts Are Pluripotent Adult Stem Cells that Underlie Planarian Regeneration
Investigators used ionizing radiation and single-cell transplantation to identify neoblasts that can form large descendant-cell colonies in vivo. [Science]

Computational Design of Proteins Targeting the Conserved Stem Region of Influenza Hemagglutinin
Researchers describe a general computational method for designing proteins that bind a surface patch of interest on a target macromolecule. [Science]

Apogossypol Derivative BI-97C1 (Sabutoclax) Targeting Mcl-1 Sensitizes Prostate Cancer Cells to mda-7/IL-24–Mediated Toxicity
Scientists demonstrate that pharmacological inhibition of myeloid cell leukemia-1 (Mcl-1) expression with the unique Apogossypol derivative BI-97C1 (Sabutoclax) is sufficient to sensitize prostate tumors to melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24)–induced apoptosis, whereas ABT-737, which lacks efficacy in inhibiting Mcl-1, does not sensitize mda-7/IL-24–mediated cytotoxicity. [Proc Natl Acad Sci U S A]

Multiple Recognition Assay Reveals Prostasomes as Promising Plasma Biomarkers for Prostate Cancer
Investigators developed an extremely sensitive and specific assay for detection of complex target structures such as microvesicles in which the target is first captured via an immobilized antibody and subsequently detected by using four other antibodies with attached DNA strands. [Proc Natl Acad Sci U S A]

Generation of Induced Pluripotent Stem Cells from Human Kidney Mesangial Cells
Researchers reprogrammed normal human mesangial cells to pluripotency by retroviral transduction using defined factors (OCT4, SOX2, KLF4 and c-Myc). [J Am Soc Nephrol]

More Briefs Coming in Stem Cell Lawsuit
After months of inactivity, a lawsuit challenging the legality of National Institutes of Health funding for human embryonic stem cell research could soon be moving again. [U.S. Federal Appeals Court, United States]

A Clearer Regulatory Pathway for Cell Therapy may Help Improve Investment
Cell therapy took an important step forward recently in the U.S. when the Centers for Medicare & Medicaid Services suggested that the federal government reimburse older men who use Dendreon’s drug Provenge for the approved hormone-refractory prostate cancer indication. [Centers for Medicare & Medicaid Services, United States]

Regenerative Medicine Act of 2011 Introduced in House of Representatives, with Support from the Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine announced the introduction of the Regenerative Medicine Act of 2011 (H.R. 1862) in the U.S. House of Representatives and expressed appreciation for the efforts of its lead sponsors, Reps. Brian P. Bilbray and Diana DeGette. [The Alliance for Regenerative Medicine, United States]

U.S. Broadens Job Prospects for Foreign Grads in Science Fields
U.S. Department of Homeland Security announced that it was expanding the list of disciplines eligible for the extension in immigration rules. The revised list adds fields such as neuroscience, marine science, environmental science, pharmaceutics and drug design, and education research. [U.S. Department of Homeland Security, United States]

Authorities Shut Controversial German Stem Cell Clinic
Health authorities in Germany have shut down a large clinic that had been peddling unproven stem cell treatments for a variety of physical disorders, including cerebral palsy, Parkinson’s disease, and spinal cord injury. [German Health Authorities, Germany]

In Spain, a High-Profile Spat Over Drug Development Funds
Spain’s top cancer scientist is fighting with the government over a plan to use private funding to develop drugs against lung cancer—and both parties have chosen the media as their battleground. [Spanish Ministry of Science and Innovation, Spain]

Australian Government Silent on Synchrotron Budget While Scientists Plan Expansion
One might think that the managers of the Australian Synchrotron would be panicking given the news that neither the federal government nor the Victoria state government has addressed in their just-released budget proposals how the facility will be funded beyond June 2012, when its original 5-year financial plan ends. Yet, at least publicly, those running the synchrotron are thinking not about how to save the young facility but how to grow it. [Australian Federal Government, Australia]

Science Escapes Cuts in Australian Budget
Despite cuts of about Aus $22 billion (US $24 billion) in the 2011–12 Australian budget, announced on 10 May, scientists are relieved that spending on the major research agencies has been maintained. [Australian Government, Australia]

Ten-Year Plan Aims to Make Slovenia a Regional Science Leader
Slovenia’s parliament is expected to approve a 10-year strategy to give the country’s research and innovation sectors a major facelift. [Slovenian Parliament, Slovenia]

Stem Cell Standardization Deal Inked Between New Players Sistemic and Leaders Roslin Cells
Sistemic Ltd and Roslin Cells Ltd signed a Memorandum of Understanding to promote the development of new technologies for the standardization of the manufacture of stem cells for their use in cell therapy and drug development screening. [Sistemic Ltd. Press Release]

Oncolytics Biotech® Inc. Enters into Commercial Supply Agreement with SAFC®
Oncolytics Biotech Inc. announced that it has entered into a commercial supply agreement with SAFC for the commercial manufacture of REOLYSIN®, Oncolytics’ proprietary reovirus. [Oncolytics Biotech Inc. Press Release]

Medistem Initiates Collaboration with Bakoulev Center for Developing Next Generation Cardiac Stem Cell Therapeutics
Medistem Inc. announced a collaboration with the Bakoulev Center of Cardiovascular Surgery of Russian Academy of Sciences. [Marketwire]

University of Ottawa Signs Agreement with the Centre for Drug Research and Development (CDRD)
The University of Ottawa and CDRD announced that they have signed an affiliation agreement that will allow researchers at the University of Ottawa to access CDRD’s drug development infrastructure and expertise. [Centre for Drug Research and Development Press Release]

Myriad Genetics Licenses Novel Technology from Chronix Biomedical
Myriad Genetics, Inc. announced that it has signed an agreement to license proprietary technology for the early detection of cancer from Chronix Biomedical of San Jose, California. [Myriad Genetics, Inc. Press Release]

Shire on Hunt for Assets in Stem Cells, Genetics
British drugmaker Shire Plc would like to acquire experimental products derived from stem cells, but the company’s chief executive said it is hard to find assets that are likely to make money. [Reuters]

Mega Gift Strengthens UPenn Med School
A power couple in Philadelphia philanthropy, Raymond and Ruth Perelman, have made one of the largest gifts ever to a medical school: $225 million to the University of Pennsylvania (UPenn) School of Medicine. [ScienceInsider]

OGI Genomics Researchers Awarded $23 Million
The Ontario Genomics Institute (OGI) is pleased to announce the investment of over $23.8 million ($11.3 million from Genome Canada, $12.5 million from co-funding) into the province to support genomics research. [Ontario Genomics Institute Press Release]

First U.S. Patient Enrolled in Stem Cell Transplantation/Cardiac Bypass Study Aimed at Improving Heart Failure
A 59-year-old Houston man became the first individual in the United States to enroll in a study using stem cell transplantation during cardiac bypass to treat severe heart failure. [The Methodist Hospital System Press Release]

Nation’s Second Participant Enrolls in Human Embryonic Stem Cell Trial
Researchers at Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine and The Rehabilitation Institute of Chicago recently enrolled their first subject in a national clinical research trial of a human embryonic stem cell-based therapy for participants with a subacute thoracic spinal cord injury. [Northwestern Memorial Hospital Press Release]

The Sanford Project & DiaMedica Announce Successful Type 1 Diabetes NOD Mouse Study with DM-199
The Sanford Project & DiaMedica announced the successful completion of a study involving DM-199 in preventing the onset of Type 1 diabetes in the non-obese diabetic mouse model. [DiaMedica, Inc. Press Release]

Amsterdam Molecular Therapeutics Provides Status Update on Glybera®
Amsterdam Molecular Therapeutics provided a status update on Glybera (alipogene tiparvovec), its gene therapy product under development for the treatment of lipoprotein lipase deficiency (LPLD). [Amsterdam Molecular Therapeutics Press Release]

FDA Approves Merck’s VICTRELIS™ (boceprevir), First-in-Class Oral Hepatitis C Virus (HCV) Protease Inhibitor
Merck announced that the U.S. Food and Drug Administration has approved VICTRELIS™ (boceprevir), the company’s innovative new medicine for the treatment of chronic hepatitis C. [Merck Press Release]

New Drug Applications Submitted in the United States and Europe for Vemurafenib in Advanced Skin Cancer
Roche announced that the company submitted a New Drug Application for vemurafenib (RG7204, PLX4032) to the U.S. Food and Drug Administration and a Marketing Authorization Application to the European Medicines Agency for approval for people with BRAF V600 mutation-positive metastatic melanoma. [Roche Press Release]

Foundation Medicine Board of Directors Appoints Michael J. Pellini, M.D., President and Chief Executive Officer
Foundation Medicine, Inc. announced that cancer diagnostics industry leader Michael J. Pellini, M.D., president and chief executive officer. Dr. Pellini succeeds founding CEO Alexis Borisy, who will remain on Board of Directors and will assume the position of Chairman. [Foundation Medicine, Inc. Press Release]

Dean/CEO Edward D. Miller to Retire in 2012
President Ronald J. Daniels sent a broadcast e-mail message to faculty and staff members at The Johns Hopkins University on Wednesday, May 4, announcing the decision to Edward D. Miller, dean of the Johns Hopkins School of Medicine and CEO of Johns Hopkins Medicine, to retire in 2012. [Johns Hopkins University Press Release]

Mr. Riera Joins SymBio as Director of Business Development
SymBio Pharmaceuticals Limited is pleased to announce that Mr. Abel Riera Corominas has joined the company as Director of Business Development, bringing over 15 years of commercial expertise in Biotech and Pharma to the Business Development team. [SymBio Pharmaceuticals Limited Press Release]

Clemson University’s Karen Burg Elected President of Scientific Society
Clemson University bioengineering professor Karen Burg has been elected president of the Society For Biomaterials. [Clemson University Press Release]

Texas’s Cancer Fund Lures Leading Stem Cell Researcher
University of Michigan, Ann Arbor, stem cell researcher Sean Morrison has been wooed to Texas by its $3 billion state cancer research program. [ScienceInsider]

Pitt Medicine Prof Awarded for Career Achievement in Research
Michael J. Fine, M.D., M.Sc., has received the 2011 John M. Eisenberg Award for Career Achievement in Research at the annual meeting of the Society of General Internal Medicine. [University of Pittsburgh Medical Center Press Release]

Tekmira Provides Corporate Update and Announces First Quarter 2011 Results
Tekmira Pharmaceuticals Corporation announced its financial and operational results for the first quarter ended March 31, 2010. [Tekmira Pharmaceuticals Corporation Press Release]

Yale and Rush University Scientists Receive Sanberg Awards from ASNTR
At the 18th Annual Conference of the American Society of Neural Therapy and Repair (ASNTR), held in conjunction with the 11th International Conference on Neuronal Transplantation and Repair, the ASNTR awarded The 2011 Bernard Sanberg Memorial Award for Brain Repair to Donald Eugene Redmond, MD, professor of neurosurgery, Yale University School of Medicine. [EurekAlert! Press Release]

NIH Director: Fewer Than One in Five Grant Applications May Get Funded This Year
At a Senate hearing, National Institutes of Health Director Francis Collins warned that the fraction of grant applications that are funded this year could drop below 20% for the first time.

Center for Scientific Review; Notice of Closed Meetings (FR Doc No: 2011-11397)

Center for Scientific Review; Notice of Closed Meetings (FR Doc No: 2011-11661)

Center for Scientific Review; Notice of Closed Meetings (FR Doc No: 2011-11661)

Center for Scientific Review; Notice of Closed Meeting (FR Doc No: 2011-11938)

Center for Scientific Review; Notice of Closed Meetings (FR Doc No: 2011-11960)

Center for Scientific Review; Cancellation of Meeting (FR Doc No: 2011-11404)

Center for Scientific Review; Amended Notice of Meeting (FR Doc No: 2011-11663)

Center for Scientific Review; Amended Notice of Meeting (FR Doc No: 2011-11667)

Center for Scientific Review; Amended Notice of Meeting (FR Doc No: 2011-11780)

Center for Scientific Review; Amended Notice of Meeting (FR Doc No: 2011-11786)

Center for Scientific Review; Amended Notice of Meeting (FR Doc No: 2011-11921)

Center for Scientific Review; Amended Notice of Meeting (FR Doc No: 2011-11949)

National Cancer Institute; Notice of Meeting (FR Doc No: 2011-11402)

National Cancer Institute; Notice of Closed Meetings (FR Doc No: 2011-11956)

National Cancer Institute; Notice of Closed Meeting (FR Doc No: 2011-11957)

National Institutes of Health Notice of Meeting (FR Doc No: 2011-11791)

National Human Genome Research Institute; Notice of Closed Meeting (FR Doc No: 2011-11803)

National Center for Research Resources; Notice of Closed Meeting (FR Doc No: 2011-11530)

Laboratory Animal Welfare: Proposed Adoption and Implementation of the Eighth Edition of the Guide for the Care and Use of Laboratory Animals (FR Doc No: 2011-11490)

Office of Biotechnology Activities; Recombinant DNA Research: Action Under the NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines) (FR Doc No: 2011-11668)

Notice of Correction in Review Criteria for PA-10-071: NIH Support for Conferences and Scientific Meetings (Parent R13/U13) (NOT-OD-11-074)

Notice of Opportunity for Fast Track Entry of Assay Projects for High Throughput Screening into the NIH Roadmap Molecular Libraries Probe Production Centers Network (NOT-RM-11-018)

Modification of RFA-RM-10-020: Institutional Clinical and Translational Science Award (CTSA) (U54) (NOT-RM-11-017)

Modification of PAR-11-136: Limited Competition: National Primate Research Centers (P51) (NOT-RR-11-006)

FOOD AND DRUG ADMINISTRATION (United States)

FDA Requests Input on Development of User Fee Program for Biosimilar and Interchangeable Biological Products
The U.S. Food and Drug Administration is requesting input from stakeholders and the public relating to the development of a user fee program for biosimilar and interchangeable biological product (351(k)) applications.

FDA to Issue Biosimilar Guidance in 2011
The U.S. Food and Drug Administration expects to issue this year general guidance for companies seeking to market generic versions of biotechnology drugs, a top agency official said.

FDA Official Sees Drug Approvals Rising
The U.S. Food and Drug Administration is seeing a rising number of new drugs ready for approval and expects a gradual increase in medicines that reach the market, a top agency official said.

Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Guidance for Industry on Updating Labeling for Susceptibility Test Information in Systemic Antibacterial Drug Products and Antimicrobial Susceptibility Testing Devices [FR Doc No: 2011-11359]

Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Information From United States Firms and Processors That Export to the European Community [FR Doc No: 2011-11360]

Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Investigational New Drug Regulations [FR Doc No: 2011-11540]

Proposal To Withdraw Approval for the Breast Cancer Indication for Bevacizumab; Hearing [Docket No. FDA-2010-N-0621]

Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Orphan Drugs; Common European Medicines Agency/Food and Drug Administration Application Form for Orphan Medicinal Product Designation (Form FDA 3671) [FR Doc No: 2011-11744]

MEDICINES AND HEALTHCARE REGULATORY AGENCY (United Kingdom)

Drug Safety Update: May 2011 (Volume 4, Issue 10)

THERAPEUTIC GOODS ADMINISTRATION (Australia)

Streamlined Submission Process for Prescription Medicines
Added information about workshops being held in Brisbane, Melbourne & Sydney in June.

Way Cleared for Improved Access to Generic Medicines
Australian consumers and health professionals will have more ready access to generic medicines following the passage of legislation through the Senate.

Regulatory and Technical Consultative Forum for Medical Devices (RegTech Forum)
The RegTech Forum is established as a consultative forum to facilitate consultation between the TGA and the medical devices industry.

Guidance on the GMP Clearance of Overseas Medicine Manufacturers
The Australian Regulatory Guidelines GMP Clearance for Overseas Manufacturers (17th edition) will be phased in over the next 3 months.

NEW CIRM/Regenerative Medicine Consortium – Imaging Technology for Cellular Therapies
May 26, 2011
Webinar

NEW Gordon Research Conferences: Tissue Repair & Regeneration
June 5-10, 2011
New London, United States

NEW Asylum Research UK Forum and User Meeting
June 21, 2011
Edinburgh, United Kingdom 

NEW Gordon Research Conferences: Cell Growth & Proliferation – Connecting Cell Cycle Regulation to Cancer Biology
June 26-July 1, 2011
Biddeford, United States

Visit our events page to see a complete list of events in the cell, gene and immunotherapy community.

Staff Scientist Position (Spanish National Cancer Center)

Postdoctoral Research Fellows (Stem Cells) (A*Star Bioprocessing Technology Institute) 

Quality Assurance Manager – Program in Children’s Regenerative Medicine (The University of Texas Medical School at Houston)

Implementation Coordinator – Maternity Leave Contract (STEMSOFT Software Inc.) 

Tenure Track, Assistant/Associate Professor (University of Missouri-Kansas City School of Medicine)

Postdoc – Laboratory of Molecular Tumor Genetics (Duke-NUS Graduate Medical School)

Postdoctoral Positions in Immune Cell Activation (Institut de Recherches Cliniques de Montréal)

Postdoctoral Position in Developmental Neurobiology (Institut de Recherches Cliniques de Montréal)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Cell Therapy News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.